SCIENTURE Holdings Announces Full Repayment and Conversion of Outstanding Debentures, Strengthening Balance Sheet
COMMACK, NY, Oct. 08, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:…
Checkerspot and Huvepharma Partner to Commercialize Groundbreaking Human Milk Fat Analog
Clearing a Major Technological Hurdle, Checkerspot & Huvepharma Ready to Scale Production…
Ipsen – September 2025 – Monthly information relative to the total number of voting rights and shares composing the share capital
Monthly information relative to the total number of voting rights and shares…
NeXtGen Biologics Announces Issuance Of A Third New Patent Covering Axolotl-Derived Technology
GAINESVILLE, Fla., Oct. 07, 2025 (GLOBE NEWSWIRE) -- NeXtGen Biologics announces the…
Vivoryon Therapeutics N.V. Successfully Completes Private Placement Raising EUR 5.1 Million
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR…
BioRestorative Therapies Announces $1.085 Million Registered Direct Offering Priced Above Market
MELVILLE, N.Y., Oct. 06, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”,…
EssilorLuxottica: Third-Quarter 2025 Revenue Conference Call Invitation
Third-Quarter 2025 RevenueConference Call Invitation Mr STEFANO GRASSI, Chief Financial Officer, andMr…
Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinsons Disease and Movement Disorders
– ARV-102 was well tolerated in clinical trials for both healthy volunteers…
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety…
